4445-40-3

Usage

Uses

Used in Pharmaceutical Industry:
4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID is used as an intermediate in the synthesis of various drugs, such as antihypertensive and antidiabetic medications, for the treatment of high blood pressure and diabetes, respectively.
Used in Agrochemical Industry:
This chemical compound is used as an intermediate in the manufacturing of agrochemicals, which are essential for the protection and enhancement of crop yields.
Used in Dye and Pigment Industry:
4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID is used as a starting material for the synthesis of dyes and pigments, which are important for coloring various products in industries such as textiles, plastics, and paints.
Used in Organic Compounds Synthesis:
It serves as a starting material for the synthesis of other organic compounds, contributing to the development of new chemical products and technologies.
Regulation of Exposure:
Due to its potential carcinogenic properties, 4'-AMINO-BIPHENYL-3-CARBOXYLIC ACID exposure is strictly regulated in many countries to minimize potential health hazards for workers and the general population.

Upstream product

• 108620-13-9 2-acetylamino-5-phenylbenzoic acid 
• 92-95-5 4-biphenyl isocyanate 
• 109496-98-2 5‐phenylindoline‐2,3‐dione 
• 20780-76-1 5-iodoisatin 
• 60313-92-0 p-iodoisonitrosoacetanilide 
• 540-37-4 p-aminoiodobenzene 
• 63040-30-2 N-(3-methyl-biphenyl-4-yl)-acetamide 
• 5152-76-1 N-chloro-2'-methylacetanilide 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 98-80-6 phenylboronic acid 
• 584-08-7 potassium carbonate 
• 851314-03-9 methyl 5-bromo-2-((tert-butoxycarbonyl)amino)benzoate 
• 134-20-3 2-carbomethoxyaniline 
• 243989-52-8 4-amino-biphenyl-3-carboxylic acid methyl ester 

Downstream Products

• 206190-28-5 6-phenylquinazolin-4(3H)-one 
• 1046152-56-0 C₂₆H₁₈O₄Se₂ 
• 1237744-77-2 2-methyl-6-phenyl-4H-benzo[d][1,3]oxazin-4-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo

Although gastric cancer has become a major public health problem, oral agents applied in clinics for gastric cancer therapy are scarce. Therefore, to explore new oral chemical entities with high efficiency and low toxicity, 41 o-aminobenzamide derivatives based on the scaffolds of MS-275 and SAHA were designed, synthesized, and evaluated for their anti-gastric cancer abilities in vitro and in vivo. Structure-activity relationships were discussed, leading to the identification of compounds F8 (IC50 = 0.28 μM against HGC-27 cell) and T9 (IC50 = 1.84 μM against HGC-27 cell) with improved cytotoxicity, anti-gastric cancer proliferation potency, induction of cell apoptosis and cell cycle arrest ability, inhibition of cell migration and invasion. What is worth mentioning is that compound F8 was more efficient and less toxic than the positive drug capecitabine in vivo on the HGC-27-xenograft model. Meanwhile, compound F8 exhibited suitable pharmacokinetic properties and less acute toxicity (LD50 > 1000 mg/kg). Besides, western blotting analysis, IHC analysis, differentially expressed proteins analysis and ABPP experiment indicated that compound F8 could modulate molecular pathways involved in apoptosis and cell cycle progression. Consequently, compound F8 is a strong candidate for the development of human gastric cancer therapy.

Selenium-catalyzed intramolecular atom- And redox-economical transformation ofo-nitrotoluenes into anthranilic acids

Anthranilic acids (AAs) are significant basic chemicals used in pharmaceuticals, agrochemicals, dyes, fragrances,etc. Superfluous steps are always involved in obtaining AAs. Herein, we demonstrate a straightforward strategy to transform abundanto-nitrotoluenes into biologically and pharmaceutically significant AAs without any extra reductants, oxidants and protecting groups. Various sensitive groups, such as halogens, sulfide, aldehyde, pyridines, quinolines,etc., can be tolerated in this transformation. A hundred-gram-scale operation is realized efficiently with almost quantitative selenium recycling. Further mechanistic studies and DFT calculations disclosed the proposed atom-exchange processes and the key roles of the selenium species.

Anthranilic acid and derivatives thereof as well as synthesis method and application thereof

In the reaction solvent, o-methyl (hetero) aryl nitro compound is taken as a reaction raw material and is used for water. The anthranilic acid and its derivatives are synthesized by the action of a catalyst, a base and an additive. The synthetic method has the advantages of cheap and easily available raw materials, simple reaction operation, high yield and excellent functional group tolerance, and provides a simple and efficient method for synthesizing o-aminobenzoic acid which is widely used in the aspects of dyes, medicines, pesticides, spices and the like. The invention further discloses the anthranilic acid and derivatives and application thereof, and has a wide application prospect.

PFKFB3 INHIBITORS AND THEIR USES

This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.

Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening

Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis, remains the leading cause of death from a single infectious agent worldwide. The emergence of drug-resistant M.tb strains stresses the need for drugs acting on new targets. Mycolic acids are very long chain fatty acids playing an essential role in the architecture and permeability of the mycobacterial cell wall. Their biosynthesis involves two fatty acid synthase (FAS) systems. Among the four enzymes (MabA, HadAB/BC, InhA and KasA/B) of the FAS-II cycle, MabA (FabG1) remains the only one for which specific inhibitors have not been reported yet. The development of a new LC-MS/MS based enzymatic assay allowed the screening of a 1280 fragment-library and led to the discovery of the first small molecules that inhibit MabA activity. A fragment from the anthranilic acid series was optimized into more potent inhibitors and their binding to MabA was confirmed by 19F ligand-observed NMR experiments.

Precursor-Directed Syntheses and Biological Evaluation of New Elansolid Derivatives

The antibiotic elansolid C1 (8) was isolated from Chitinophaga sancti strain FxGBF13 after fermentation in the presence of anthranilic acid. Remarkably, 8 was also obtained by addition of anthranilic acid to a crude fermentation extract containing the mac

ORGANOMETALIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME

The present invention relates to organic electroluminescent compounds and electroluminescent devices comprising the same as host material. The electroluminescent compounds according to the invention are characterized by having three ligands, two bivalent metals and a monovalent anion derived from an inorganic or an organic acid.

Direct synthesis of new arylanthranilic acids via a Suzuki cross-coupling reaction from iodoisatins

Direct synthesis of new arylanthranilic acids via a Suzuki cross-coupling reaction with iodoisatins as key intermediates is described. A 'one pot' procedure is proposed.

1H-IMIDAZO[4,5-c]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

Inhibitors of farnesyl protein transferase

The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.